Correction Volume 12, Issue 5 pp 4678—4679

Yinjie Su^{1, *,} , Weilian Feng^{2, *,} , Guanglei Zhong^3, , Yiyao Ya^1,4, , Zehu Du^5, , Juanyi Shi^1, , Luping Chen^6, , Wen Dong^1, , Tianxin Lin^1, ,

Received: February 19, 2020       Accepted: March 27, 2020       Published: March 2, 2020      

Copyright © 2020 Su et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The authors requested the replacement of Figure 4E and Table 1. Figure 4E (ciRs-6+miR-nc) was quite similar to Supplementary Figure 1D (si-3 in T24 cells) and was slightly updated. Changes of Table 1 are done to correct the statistical mistakes.

These corrections do not change the content of the publication and do not affect the conclusion of this research. The authors apologize for the unintentional mistakes.

The corrected Figure and Table are provided below.

Figure 4. miR-653 rescues the tumor suppressive effect of ciRs-6 in bladder cancer. (E) Clone formation assays were used to evaluate clone forming ability.

Table 1. Relationship between ciRs-6 level and clinical characteristics in bladder cancer.

Total		Patients	Expression of ciRs-6
			High	Low	p
Age(mean)		50	47.931	52.069	0.395
Gender
	Male	45	22	23	0.753
	Female	13	7	6
Tumor stage
	Tis/Ta/T1	31	22	9	<0.001
	T2	17	7	10
	T3/T4	10	0	10
Grade
	High	20	5	15	0.006
	Low	38	24	14
Number of tumors
	Solitary	41	23	18	0.149
	Multiple	17	6	11
Lymph node metastasis
	Negative	23	13	10	0.421
	Positive	35	16	19
Follow-up (month, mean)		33.23	33.00	33.45	0.047